CClinicalTrials.gg
CompletedNCT07171021theophyllineUpdated Sep 12, 2025

The Effect of Oral Theophylline on Traumatic Anosmia

A Phase 4 interventional study of Theophylline 200 mg and olfactory training in Traumatic Anosmia, sponsored by Taichung Veterans General Hospital. Completed at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Taichung Veterans General Hospital · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 9 months after the study started (first participant enrolled Dec 2020, registered Sep 2025).
Phase
Phase 4
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aimed to improve the treatment outcomes of patients with post-traumatic anosmia through medication and olfactory training. Number of subjects and selection criteria: 160 patients were enrolled in the ENT and head and neck outpatient clinic with a history of head trauma, a complaint of anosmia, and evidence of olfactory examination. Their olfactory status had not improved after steroids, zinc tablets, and olfactory training. Exclusion criteria: Patients under 20 years of age, pregnant or breastfeeding women, and those with compromised immune systems were excluded.

Patients who did not improve after medication and olfactory training were randomized. One group received theophylline and zinc tablets with continued olfactory training, while the other group received zinc tablets alone with continued olfactory training. Patients returned for follow-up and medical consultation after treatment at the 24th week. Theophylline medication: Theophylline (200 mg, two tablets twice daily) was administered for 24 weeks.

Read the detailed description

We collected subjects who complained of a complete loss of their smell function (anosmia) after an episode of head injury between December 2020 and December 2023. Any patient who had a history of loss of olfactory function before head trauma or sinus surgery was excluded from the study. If the etiology of loss of olfactory function was suspected to not be caused by head trauma, it was also excluded. The remaining patients received right and left unilateral phenyl ethyl alcohol (PEA) odor detection threshold tests to assess their olfactory function. The definition of anosmia in this study was that the unilateral PEA thresholds for the right and left were -1. Anosmic patients were included in this study. These anosmic patients were then treated with high-dose prednisolone (1 mg/kg per day for 3 days) with tapering, along with zinc gluconate (10 mg three times a day) for a period of 1 month. Classic OT using 4 separate bottles of PEA, lemon, eucalyptus, and clove oil was also started. The patients were told to sniff each odorant for 10 seconds, twice a day.21 After one month of treatment, all patients received unilateral right and left PEA odor detection threshold tests and the traditional Chinese version of the University of Pennsylvania Identification Test (UPSIT-TC) to assess their olfactory function. Those whose unilateral PEA thresholds on the right and left remained -1 were enrolled in this study.

The eligible patients were randomly divided into 2 groups. Randomized assignment to the two groups was performed by an independent statistician. The patients in the theophylline group took theophylline (400 mg twice a day) for 6 months and continued OT. Those who were assigned to the OT group continued OT for 6 months without any other form of treatment.

All patients returned to the clinic to receive another series of unilateral right and left PEA threshold tests and UPSIT-TC at the end of 6 months of treatment. Patients taking oral theophylline also received blood tests to measure blood theophylline levels. Brain magnetic resonance imaging (MRI) was performed to measure the volumes of olfactory bulbs (OB) following completion of the 6-month treatment. During the 6-month treatment period, drugs such as oral or nasal steroids, vitamin A, zinc, and antihistamines were not allowed.

02

Conditions studied

  • Traumatic Anosmia

Keywords

  • olfactory training, smell identification, smell threshold, theophylline, traumatic anosmia
03

In context

Lead sponsor

Taichung Veterans General Hospital is the lead sponsor of 170 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • subjects who complained of a complete loss of their smell function (anosmia) after an episode of head injury.

Exclusion criteria

Exclusion Criteria:

  • patients without a complete loss of their smell function
  • a history of loss of olfactory function before head trauma or sinus surgery
  • the etiology of loss of olfactory function was suspected to not be caused by head trauma
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    theophylline arm

    theophylline (400 mg twice a day) and olfactory training for 6 months

    Drug: Theophylline 200 mg · Behavioral: olfactory training

  • Active comparator
    control arm

    olfactory training for 6 months

    Behavioral: olfactory training

Interventions

  • DrugTheophylline 200 mg

    taking theophylline (400 mg twice a day) and performing olfactory training for 6 months

  • Behavioralolfactory training

    performing olfactory training for 6 months

06

What researchers measure

Primary outcomes

  1. Change of olfactory identification ability of participants with treatment as assessed by Traditional Chinese Version of the University of Pennsylvania Identification Test

    The test consists of 40 tests as it follows the North American version of the University of Pennsylvania Smell Identification Test. In each test, the brown strip at the bottom of the test page consists of microcapsules of an odorant that are released by scratching the strip with a pencil tip. The patient sniffs the released odorant and selects a response from four odor descriptor options that are used to identify the odorant. The test score is the number of correct responses among the 40 tests taken.

    Time frame: From enrollment to the end of treatment at 7 months

  2. Olfactory threshold change of participants with intervention drug as assessed by phenyl ethyl alcohol odor detection threshold test

    The test uses different concentrations of a phenyl ethyl alcohol odorant to measure a patient's odor detection threshold. The strongest concentration is a concentration of phenyl ethyl alcohol at 10-1 log vol/vol. Then, the concentration of the odorant is diluted with mineral oil in half-log steps until the weakest concentration at 10-9 log vol/vol. A 2-alternative forced choice single-staircase procedure is used to decide the odor detection threshold. The threshold ranges from -1 to -9.

    Time frame: From enrollment to the end of the treatment at 7 months

07

Study locations

1 site
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
08

References and documents

Publications

  • Henkin RI, Velicu I, Schmidt L. An open-label controlled trial of theophylline for treatment of patients with hyposmia. Am J Med Sci. 2009 Jun;337(6):396-406. doi: 10.1097/MAJ.0b013e3181914a97. PubMed 19359985 ↗

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication

Supporting information: Study protocol, Sap, Icf

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07171021
Lead sponsor
Taichung Veterans General Hospital
Responsible party
Rong-San Jiang (Visiting Doctor, Taichung Veterans General Hospital) — Principal investigator
First posted
Sep 12, 2025
Start date
Dec 1, 2020
Primary completion
Dec 31, 2023
Completion
Jun 30, 2024
Last update
Sep 12, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion